Ερευνητικό υλικό ΕΚΠΑ

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group

Αγγλικά

Δεν υπάρχει περίληψη

2018

Papageorgiou, S.G.
Kotsianidis, I.
Kontos, C.K.
Symeonidis, A.
Galanopoulos, A.
Hatzimichael, E.
Poulakidas, E.
Diamantopoulos, P.
Vassilakopoulos, T.P.
Zikos, P.
Papadaki, H.
Bouronikou, E.
Panayiotidis, P.
Viniou, N.-A.
Pappa, V.

Leukemia Research

Elsevier Ireland Ltd

71

55-59

azacitidine; antineoplastic antimetabolite; azacitidine, adult; aged; body mass; body surface; drug effect; drug efficacy; drug response; female; follow up; high risk patient; human; Letter; major clinical study; male; myelodysplastic syndrome; overall survival; priority journal; risk factor; survival rate; treatment outcome; body mass; dose response; Greece; middle aged; myelodysplastic syndrome; retrospective study; very elderly, Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Body Mass Index; Dose-Response Relationship, Drug; Female; Greece; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome

https://doi.org/10.1016/j.leukres.2018.07.004

10.1016/j.leukres.2018.07.004

https://pergamos.lib.uoa.gr/uoa/dl/object/3087480